{SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, GPCR Modulators, GPCR Proteins, Modulators and Antibodies, GlaxoSmithKline, Membrane Protein Biology Tools, Neuropeptides, Peptides and Proteins, Peptides for Cell Biology,
{SNA} Approved Therapeutics/Drug Candidates,
Approved Therapeutics/Drug Candidates, Biochemicals and Reagents, Cell Biology, Cell Signaling and Neuroscience, GPCR Modulators, GPCR Proteins, Modulators and Antibodies, GlaxoSmithKline, Membrane Protein Biology Tools, Neuropeptides, Peptides and Proteins, Peptides for Cell Biology, Proteins and Derivatives, Urotensin - Receptor Antagonists, Urotensins
相关文献及参考
[2]. Behm DJ, et al. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br J Pharmacol. 2008 Oct;155(3):374-86.
[3]. Watson AM, et al. Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. Diabetologia. 2013 May;56(5):1155-65.
Behm, D.J., et al., Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br. J. Pharmacol. 155 , 374-386, (2008) 摘要
Douglas, S.A., et al., Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br. J. Pharmacol. 145 , 620-635, (2005)
[1]. Park SL, et al. Inhibitory Effect of an Urotensin II Receptor Antagonist on Proinflammatory Activation Inducedby Urotensin II in Human Vascular Endot